25,474 Shares in Regeneron Pharmaceuticals, Inc. $REGN Purchased by VIRGINIA RETIREMENT SYSTEMS ET Al

Key Points

• Virginia Retirement Systems purchased 25,474 Regeneron shares worth approximately $15.9 million in the second quarter. Institutional investors collectively own 83.31% of the company.
• Analysts maintain a generally positive outlook, with 14 Buy ratings and 10 Hold ratings. Regeneron has a consensus price target of $800.36 and an overall “Moderate Buy” rating.
• Regeneron exceeded quarterly expectations, reporting $14.29 in EPS versus the $10.16 consensus and $4.29 billion in revenue, up 16.7% year over year. The company also pays a quarterly dividend of $0.94 per share.

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 25,474 shares of the biopharmaceutical company's stock, valued at approximately $15,884,000.

Several other hedge funds have also recently added to or reduced their stakes in REGN. Brighton Jones LLC grew its stake in shares of Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock worth $675,000 after acquiring an additional 686 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Regeneron Pharmaceuticals during the first quarter worth $226,000. Arrowstreet Capital Limited Partnership acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at $3,183,000. Gabelli Funds LLC raised its stake in Regeneron Pharmaceuticals by 3.0% during the 2nd quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company's stock valued at $978,000 after purchasing an additional 55 shares during the last quarter. Finally, Sei Investments Co. boosted its holdings in Regeneron Pharmaceuticals by 18.8% in the 2nd quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company's stock valued at $16,985,000 after purchasing an additional 5,120 shares during the period. Institutional investors own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on REGN. HSBC lowered their price target on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a "buy" rating on the stock in a research note on Monday, July 6th. Guggenheim raised their price objective on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a "buy" rating in a research report on Monday, August 3rd. Piper Sandler decreased their price objective on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an "overweight" rating on the stock in a report on Thursday, July 9th. BMO Capital Markets lowered their price objective on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an "outperform" rating on the stock in a research report on Monday, May 18th. Finally, JPMorgan Chase & Co. lowered their price objective on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an "overweight" rating on the stock in a research report on Monday, May 18th. Fourteen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $800.36.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the transaction, the director directly owned 17,303 shares of the company's stock, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the sale, the director owned 1,703 shares in the company, valued at $1,362,400. This represents a 31.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 4,146 shares of company stock worth $3,432,488 in the last quarter. Corporate insiders own 6.97% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $827.72 on Tuesday. The firm has a market cap of $85.22 billion, a P/E ratio of 20.46, a price-to-earnings-growth ratio of 1.62 and a beta of 0.20. The firm's 50-day simple moving average is $742.21 and its 200-day simple moving average is $719.75. Regeneron Pharmaceuticals, Inc. has a twelve month low of $541.00 and a twelve month high of $859.34. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.16 by $4.13. The firm had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company's quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $12.81 earnings per share. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 9.29%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.